Navigating Second-Line Treatment in Pediatric Low-Grade Glioma

Andrea Franson, MD, discusses the mechanism of action of tovorafenib and its emerging role within the evolving treatment paradigm for pLGG.

Andrea Franson, MD, MS, discusses safety data on tovorafenib in relapsed or refractory pediatric low-grade glioma from the FIREFLY-1 trial.

Cassie Kline, MD, MAS, discusses data from the phase 2 FIREFLY-1 trial of tovorafenib in relapsed/refractory pediatric low-grade glioma.

Mohamed Abdelbaki, MD, discusses second-line targeted therapy options for pediatric low-grade glioma.

Tovorafenib produced deep, durable responses in pLGG, with long treatment-free intervals and minimal tumor rebound after therapy.

Dr Kline discusses longer-term efficacy data from the FIREFLY-1 study of tovorafenib in patients with relapsed/refractory pediatric low-grade glioma.

Cassie Kline, MD, MAS, discusses 3-year follow-up data with tovorafenib in patients with pediatric low-grade glioma from FIREFLY-1.